Oculis Holding Ag (OCSAW) — SEC Filings

Overview

Oculis Holding Ag (OCSAW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Oct 31, 2025: On October 29, 2025, Oculis Holding AG announced an offering of 5,432,098 ordinary shares at $20.25 per share. This offering was conducted through an underwriting agreement with J.P. Morgan Securities LLC, Leerink Partners LLC, and Pareto Securities AB. The total gross proceeds from this offering ar

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 6 bullish, 1 bearish, 22 neutral. The dominant filing sentiment for Oculis Holding Ag is neutral.

Filing Type Overview

Oculis Holding Ag (OCSAW) has filed 23 6-K, 1 20-F, 2 SC 13G, 3 SC 13G/A with the SEC between Feb 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (29)

• 6-K Filing — 6-K · Nov 10, 2025
• Oculis Holding AG Raises ~$110M in Share Offering — 6-K · Oct 31, 2025 Risk: medium
  On October 29, 2025, Oculis Holding AG announced an offering of 5,432,098 ordinary shares at $20.25 per share. This offering was conducted through an underwriti
• Oculis Terminates $100M Share Sales Agreement — 6-K · Oct 29, 2025 Risk: medium
  Oculis Holding AG announced on October 29, 2025, that it is terminating its at-the-market (ATM) sales agreement with Leerink Partners LLC, originally dated May
• Oculis Advances Privosegtor to Registrational Program After FDA Meeting — 6-K · Oct 6, 2025 Risk: medium
  Oculis Holding AG announced on October 6, 2025, that its drug candidate, Privosegtor (OCS-05), will advance into a registrational program for neuro-ophthalmolog
• Oculis Holding AG Files 6-K with Financial Updates — 6-K · Aug 21, 2025 Risk: low
  Oculis Holding AG filed a 6-K report as of June 30, 2025. The filing includes financial data and details related to warrants and stock options. Notably, it refe
• Oculis Holding AG Amends Loan Facility with Kreos Capital — 6-K · Aug 1, 2025 Risk: low
  On July 31, 2025, Oculis Holding AG amended and restated its existing loan facility with Kreos Capital VII (UK) Limited, a fund managed by BlackRock, Inc. No fu
• Oculis Holding AG Reports AGM Results — 6-K · Jun 5, 2025 Risk: low
  Oculis Holding AG held its 2025 Annual General Meeting on June 4, 2025, in Zug, Switzerland. Shareholders approved all proposed resolutions, including the adopt
• Oculis Holding AG Announces 2025 AGM Details — 6-K · May 9, 2025 Risk: low
  Oculis Holding AG announced on May 9, 2025, the invitation to its 2025 Annual General Meeting (AGM) scheduled for June 4, 2025, in Zug, Switzerland. The filing
• Oculis Holding AG Reports Q1 2025 Financial Results — 6-K · May 8, 2025 Risk: low
  Oculis Holding AG announced its unaudited financial results for the three-month period ended March 31, 2025, on May 8, 2025. The company is a foreign issuer fil
• Oculis Holding AG Updates Clinical Programs at R&D Day — 6-K · Apr 15, 2025 Risk: medium
  On April 15, 2025, Oculis Holding AG held an R&D Day to provide updates on its clinical programs. Key highlights included progress on Phase 3 DIAMOND trials for
• Oculis Holding AG Files 2024 Annual Report — 20-F · Mar 11, 2025 Risk: medium
  Oculis Holding AG filed its 20-F for the fiscal year ending December 31, 2024. The filing, submitted on March 11, 2025, provides a comprehensive overview of the
• Oculis Holding AG Raises $100M in Share Offering — 6-K · Feb 14, 2025 Risk: medium
  On February 13, 2025, Oculis Holding AG entered into an underwriting agreement with BofA Securities Inc. and Leerink Partners LLC. This agreement is for an offe
• Oculis Holding AG Announces Positive Phase 2 Results for OCS-05 — 6-K · Jan 6, 2025 Risk: medium
  On January 6, 2025, Oculis Holding AG announced positive topline results from its Phase 2 ACUITY trial for OCS-05. The trial met its primary safety endpoint and
• SC 13G Filing — SC 13G · Dec 9, 2024
• Oculis Holding AG Discloses Insider Transactions — 6-K · Nov 29, 2024 Risk: low
  On November 29, 2024, Oculis Holding AG disclosed transactions by persons discharging managerial responsibilities (PDMRs) and their closely associated persons.
• SC 13G/A Filing — SC 13G/A · Nov 7, 2024
• Oculis Holding AG Reports Q3 2024 Unaudited Results — 6-K · Nov 7, 2024 Risk: low
  Oculis Holding AG announced its unaudited results for the three and nine month periods ended September 30, 2024, on November 7, 2024. The filing includes interi
• Oculis Holding AG Files 6-K with Q2 2024 Financials — 6-K · Aug 27, 2024 Risk: low
  Oculis Holding AG filed a 6-K report on August 27, 2024, detailing financial information as of June 30, 2024. The filing includes data on share-based compensati
• Oculis Holding AG Announces Positive Phase 2b Trial Results — 6-K · Jun 10, 2024 Risk: medium
  Oculis Holding AG announced on June 10, 2024, positive topline results from its Phase 2b RELIEF trial for licaminlimab, a novel anti-TNFα biologic eye drop. The
• Oculis Holding AG Announces AGM Results and New Financing — 6-K · May 31, 2024 Risk: medium
  Oculis Holding AG held its 2024 Annual General Meeting on May 29, 2024, announcing new appointments to its Board of Directors and Scientific Advisory Board. The
• Oculis Holding AG Q1 2024 Results Announced — 6-K · May 8, 2024 Risk: low
  Oculis Holding AG announced its unaudited results for the first quarter ended March 31, 2024, on May 8, 2024. The filing incorporates by reference the company's
• Oculis Holding AG Announces 2024 AGM Details — 6-K · Apr 29, 2024 Risk: low
  Oculis Holding AG announced its 2024 Annual General Meeting (AGM) will be held on May 29, 2024, in Zug, Switzerland. The company also furnished its 2023 Annual
• Oculis Raises $58.75M, Lists on Nasdaq Iceland — 6-K · Apr 22, 2024 Risk: medium
  Oculis Holding AG announced on April 22, 2024, the successful closing of a registered direct offering, raising gross proceeds of $58.75 million. Additionally, t
• Oculis Holding AG Announces Registered Direct Offering — 6-K · Apr 11, 2024 Risk: medium
  On April 11, 2024, Oculis Holding AG announced a registered direct offering to issue and sell 5,000,000 ordinary shares. The offering is being made to certain i
• Oculis Holding AG Reports 2023 Financial Results — 6-K · Mar 19, 2024 Risk: low
  Oculis Holding AG announced its financial results for the fiscal year ended December 31, 2023, on March 18, 2024. The company filed a Form 6-K report with the S
• Oculis Holds R&D Day, Updates Clinical Programs & Leadership — 6-K · Feb 28, 2024 Risk: medium
  Oculis Holding AG (Commission File No. 001-41636) held an R&D Day on February 28, 2024, issuing a press release to update on its clinical programs and announce
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Pivotal bioVenture Partners Lowers Oculis Stake to 5.0% — SC 13G/A · Feb 12, 2024 Risk: medium
  Pivotal bioVenture Partners Fund I, L.P. filed an amended SC 13G/A on February 12, 2024, disclosing their ownership in Oculis Holding AG. As of December 31, 202
• LSP 7 Coöperatieve U.A. Reports Passive Stake in Oculis Holding AG — SC 13G · Feb 9, 2024 Risk: low
  LSP 7 Coöperatieve U.A., an investment firm, filed an SC 13G on February 9, 2024, indicating its ownership of Ordinary Shares in Oculis Holding AG (ticker: OCS)

Risk Profile

Risk Assessment: Of OCSAW's 25 recent filings, 0 were flagged as high-risk, 13 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

• PDMR

Top Tags

capital-raise (4) · agm (4) · financial-results (4) · financing (3) · drug-development (3) · clinical-trials (3) · quarterly-report (3) · annual-report (3) · offering (3) · amendment (2)

Key Numbers

• Gross Proceeds: ~$110M — Raised from the share offering
• Shares Offered: 5,432,098 — Number of ordinary shares sold
• Price Per Share: $20.25 — Offering price for each share
• ATM Program Size: $100 million — Maximum amount of ordinary shares Oculis could sell under the terminated agreement.
• Fiscal Year End: 1231 — Indicates the end of the reporting period for the 2024 fiscal year.
• Reporting Period End: 2024-12-31 — Specific date for financial reporting within the 20-F.
• Reporting Period: Q2 2024 — Financial data pertains to this period
• Period for Expenses: 2024-01-01 to 2024-06-30 — Share-based compensation and other operating expenses are detailed for this six-month period.
• Loan Facility: CHF 50 million — Provides financial flexibility for operations and growth.
• Ordinary Shares: 5,000,000 — Number of shares to be issued in the registered direct offering.
• Nominal Value per Share: CHF 0.01 — The par value of each ordinary share being offered.
• Percentage of Class: 5.0% — The percentage of Oculis Holding AG's Ordinary Shares beneficially owned by Pivotal bioVenture Partners Fund I, L.P. as of December 31, 2023.
• Reporting Date: December 31, 2023 — The date for which the ownership information is being reported in the filing.
• CUSIP Number: H5870P102 — The unique identification number for Oculis Holding AG's Ordinary Shares.

Forward-Looking Statements

• {"claim":"Oculis Holding AG's stock price may experience downward pressure in the short term.","entity":"Oculis Holding AG","targetDate":"3 months","confidence":"medium"}
• {"claim":"Other institutional investors might re-evaluate their positions in Oculis Holding AG.","entity":"Institutional Investors","targetDate":"6 months","confidence":"low"}
• {"claim":"LSP 7 Coöperatieve U.A. will maintain its passive investment stance in Oculis Holding AG.","entity":"LSP 7 Coöperatieve U.A.","targetDate":"Next 12 months","confidence":"high"}
• {"claim":"Oculis Holding AG's stock price will not experience significant volatility directly due to this passive filing.","entity":"Oculis Holding AG","targetDate":"Next 3 months","confidence":"high"}

Related Companies

OCLS · OCS

Frequently Asked Questions